Advertisement

Vaccines and the Prevention of Dermatologic Diseases

  • Giancarlo Bessa
Chapter

Abstract

This chapter addresses vaccines directed toward the prevention of infectious diseases with dermatologic impact. The main ones are HPV infection, varicella and zoster infection, and hanseniasis. Indications, contraindications, and expected effects are elaborated upon.

Keywords

Vaccine Vaccination Infectious Antibodies Antigens HPV Varicella Zoster Herpes BCG Hanseniasis Leprosy Dermatosis 

Notes

Glossary

Anaphylaxis

A severe, potentially life-threatening allergic reaction. It can occur within seconds or minutes of exposure to an allergen. The flood of chemicals released by the immune system during anaphylaxis can lead the body into shock; the blood pressure drops suddenly and the airways narrow, blocking normal breathing. Signs and symptoms of anaphylaxis include a rapid, weak pulse, a rash, and nausea and vomiting.

Genotypes

The genotype of an organism is the inherited map it carries within its genetic code. It is the part (DNA sequence) of the genetic makeup of a cell, and therefore of an organism or individual, which determines a specific characteristic (phenotype) of that cell/organism/individual.

Revaccination

The vaccination administered some time after an initial vaccination, especially to strengthen or renew immunity.

References

  1. 1.
    American Academy of Pediatrics. Red book: 2015 report of the committee on infectious diseases. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, editors. 30th ed. Elk Grove Village; 2015.Google Scholar
  2. 2.
    Del Giudice G, Weinberger B, Grubeck-Loebenstein B. Vaccines for the elderly. Gerontology. 2015;61(3):203–10.CrossRefPubMedGoogle Scholar
  3. 3.
    Scully IL, Swanson K, Green L, Jansen KU, Anderson AS. Anti-infective vaccination in the 21st century – new horizons for personal and public health. Curr Opin Microbiol. 2015;27:96–102.CrossRefPubMedGoogle Scholar
  4. 4.
    Centers for Disease Control and Prevention. General recommendation on immunization: recommendation of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2011;60(02):1–64.Google Scholar
  5. 5.
    Prymula R, Siegrist C-A, Chlibek R, Zemlickova H, Vackova M, Smetana J, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet. 2009;374(9698):1339–50.CrossRefPubMedGoogle Scholar
  6. 6.
    Position papers [internet]. Geneva: World Health Organization [cited 2016 Feb 26]. Available from: http://www.who.int/immunization/policy/position_papers/en/.
  7. 7.
    WHO recommendations for routine immunization – summary tables [internet]. Geneva: World Health Organization [cited 2016 Feb 26]. Available from: http://www.who.int/immunization/policy/immunization_tables/en/.
  8. 8.
    Duncan CJ, Hambleton S. Varicella zoster virus immunity: a primer. J Infect. 2015;71(Suppl 1):S47–53.CrossRefPubMedGoogle Scholar
  9. 9.
    Varicella and herpes zoster vaccines: WHO position paper, June 2014. Wkly Epidemiol Rec. 2014; 89:265.Google Scholar
  10. 10.
    Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec. 2014; 89:465.Google Scholar
  11. 11.
    BCG vaccine: WHO position paper, January 2004. Wkly Epidemiol Rec. 2004; 79:27.Google Scholar
  12. 12.
    Revised BCG vaccination guidelines for infants at risk for HIV infection: WHO position paper, May 2007. Wkly Epidemiol Rec. 2007; 21:193.Google Scholar
  13. 13.
    Meyer PA, et al. Varicella mortality: trends before vaccine licensure in the United States, 1970–1994. J Infect Dis. 2000;182(2):383–90.CrossRefPubMedGoogle Scholar
  14. 14.
    Quinlivan M, Breuer J. Clinical and molecular aspects of the live attenuated Oka varicella vaccine. Rev Med Virol. 2014;24(4):254–73. doi: https://doi.org/10.1002/rmv.1789. Epub 2014 Mar 29.CrossRefPubMedGoogle Scholar
  15. 15.
    Gershon AA1, Gershon MD. Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiol Rev. 2013;26(4):728–43. doi: https://doi.org/10.1128/CMR.00052-13.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Helmuth IG, Poulsen A, Suppli CH, Mølbak K. Varicella in Europe – a review of the epidemiology and experience with vaccination. Vaccine. 2015;33(21):2406–13. doi: https://doi.org/10.1016/j.vaccine.2015.03.055. Epub 2015 Apr 1. Review.CrossRefPubMedGoogle Scholar
  17. 17.
    Marin M, Meissner HC, Seward JF. Varicella prevention in the United States: a review of successes and challenges. Pediatrics. 2008;122:e744–51.  https://doi.org/10.1542/peds.2008-0567.CrossRefPubMedGoogle Scholar
  18. 18.
    Heywood AE, Wang H, Macartney KK, McIntyre P. Varicella and herpes zoster hospitalizations before and after implementation of one-dose varicella vaccination in Australia: an ecological study. Bull World Health Organ. 2014;92:593–604. http://dx.doi.org/10.2471/BLT.13.132142CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Marin M, Güris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56:1–40.PubMedGoogle Scholar
  20. 20.
    Kim DK, Bridges CB, Harriman KH. Advisory Committee on Immunization Practices. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older: United States. Ann Intern Med. 2016;164:184.CrossRefPubMedGoogle Scholar
  21. 21.
    Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP). Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine. MMWR Morb Mortal Wkly Rep. 2008;57:258.Google Scholar
  22. 22.
    Committee on Infectious Diseases. Policy statement – Prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children. Pediatrics. 2011;128:630.CrossRefGoogle Scholar
  23. 23.
    Weibel RE, Neff BJ, Kuter BJ, et al. Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N Engl J Med. 1984;310:1409–15.CrossRefPubMedGoogle Scholar
  24. 24.
    Seward JF, Marin M, Vázquez M. Varicella vaccine effectiveness in the US vaccination program: a review. J Infect Dis. 2008;197(Suppl 2):S82.CrossRefPubMedGoogle Scholar
  25. 25.
    Vázquez M, PS LR, Gershon AA, et al. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med. 2001;344:955.CrossRefPubMedGoogle Scholar
  26. 26.
    Centers for Disease Control and Prevention (CDC). Evolution of varicella surveillance – selected states, 2000–2010. MMWR Morb Mortal Wkly Rep. 2012;61:609.Google Scholar
  27. 27.
    Zhou F, Harpaz R, Jumaan AO, et al. Impact of varicella vaccination on health care utilization. JAMA. 2005;294:797.CrossRefPubMedGoogle Scholar
  28. 28.
    Waye A, Jacobs P, Tan B. The impact of the universal infant varicella immunization strategy on Canadian varicella-related hospitalization rates. Vaccine. 2013;31:4744.CrossRefPubMedGoogle Scholar
  29. 29.
    World Health Organization. Background documents for the meeting of the Strategic Advisory Group of Experts (SAGE). 2014. http://www.who.int/immunization/sage/meetings/2014/april/presentations_background_docs/en/. Accessed on 26 Feb 2016.
  30. 30.
    Levin MJ, Gershon AA, Weinberg A, et al. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. J Infect Dis. 2006;194:247–55.CrossRefPubMedGoogle Scholar
  31. 31.
    Schmid DS, Jumaan AO. Impact of varicella vaccine on varicella-zoster virus dynamics. Clin Microbiol Rev. 2010;23(1):202–17.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:e44.CrossRefPubMedGoogle Scholar
  33. 33.
    Gershon AA, Steinberg SP. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. N Engl J Med. 1989;320:892–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Prymula R, Bergsaker MR, Esposito S, Gothefors L, Man S, Snegova N, Stefkovičova M, Usonis V, Wysocki J, Douha M, Vassilev V, Nicholson O, Innis BL, Willems P. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet. 2014;383(9925):1313–24. doi: https://doi.org/10.1016/S0140-6736(12)61461-5. Epub 2014 Jan 29.CrossRefPubMedGoogle Scholar
  35. 35.
    Macartney K1, Heywood A, McIntyre P. Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults. Cochrane Database Syst Rev. 2014;6:CD001833. doi: https://doi.org/10.1002/14651858.CD001833.pub3.CrossRefGoogle Scholar
  36. 36.
    Chaves SS, Haber P, Walton K, et al. Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995–2005. J Infect Dis. 2008;197(Suppl 2):S170.CrossRefPubMedGoogle Scholar
  37. 37.
    Hambleton S, Steinberg SP, Larussa PS, et al. Risk of herpes zoster in adults immunized with varicella vaccine. J Infect Dis. 2008;197(Suppl 2):S196–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Hales CM, Harpaz R, Joesoef MR, Bialek SR. Examination of links between herpes zoster incidence and childhood varicella vaccination. Ann Intern Med. 2013;159:739.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Ogunjimi B, van Damme P, Beutels P. Herpes zoster risk reduction through exposure to chickenpox patients: a systematic multidisciplinary review. PLoS One. 2013;8(6):e66485.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Uebe B, Sauerbrei A, Burdach S, Horneff G. Herpes zoster by reactivated vaccine varicella zoster virus in a healthy child. Eur J Pediatr. 2002;161:442–4.CrossRefPubMedGoogle Scholar
  41. 41.
    Carrillo-Santisteve P1, Lopalco PL. Varicella vaccination: a laboured take-off. Clin Microbiol Infect. 2014;20(Suppl 5):86–91. doi: https://doi.org/10.1111/1469-0691.12580.CrossRefPubMedGoogle Scholar
  42. 42.
    Gil-Prieto R, Walter S, Gonzalez-Escalada A, Garcia-Garcia L, Marín-García P, Gil-de-Miguel A. Different vaccination strategies in Spain and its impact on severe varicella and zoster. Vaccine. 2014;32(2):277–83.CrossRefPubMedGoogle Scholar
  43. 43.
    Volpi A, Gross G, Hercogova J, et al. Current management of herpes zoster. The European view. Am J Clin Dermatol. 2005;6:317–25.CrossRefPubMedGoogle Scholar
  44. 44.
    Kawai K, Gebremeskei BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis. 2009;200:1068.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–84.CrossRefGoogle Scholar
  47. 47.
    Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087.CrossRefGoogle Scholar
  48. 48.
    Hales CM, Harpaz R, Ortega-Sanchez I, et al. Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep. 2014;63:729.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Tseng HF, Smith N, Sy LS, Jacobsen SJ. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine. 2011;29:3628.CrossRefPubMedGoogle Scholar
  50. 50.
    Gagliardi AM, Gomes Silva BN, Torloni MR, Soares BG. Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev. 2012;10:CD008858.PubMedGoogle Scholar
  51. 51.
    Morrison VA, Johnson GR, Schmader KE, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60:900.CrossRefPubMedGoogle Scholar
  52. 52.
    Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin Infect Dis. 2012;54:922.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Schmader KE, Johnson GR, Saddier P, Ciarleglio M, Wang WW, Zhang JH et al.; for the Shingles Prevention Study Group. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc. 2010; 58(9):1634–41.Google Scholar
  54. 54.
    de Boer PT, Wilschut JC, Postma MJ. Cost-effectiveness of vaccination against herpes zoster. Hum Vaccin Immunother. 2014;10(7):2048–61. doi: https://doi.org/10.4161/hv.28670.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Aberg JA, Gallant JE, Ghanem KG, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58:e1.CrossRefPubMedGoogle Scholar
  56. 56.
    Pergam SA, Limaye AP, AST Infectious Diseases Community of Practice. Varicella zoster virus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):138.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Choi YJ, Park JS. Clinical significance of human papillomavirus genotyping. J Gynecol Oncol. 2016 Mar;27(2):e21.CrossRefPubMedGoogle Scholar
  58. 58.
    Gross G. Condylomata acuminata und andere HPV – assoziierte Krankheitsbilder des Genitale und der Harnröhre. Hautarzt. 2001;52:405–10.CrossRefPubMedGoogle Scholar
  59. 59.
    Sycuro LK, Xi LF, Hughes JP, Feng Q, Winer RL, Lee SK, O’Reilly S, Kiviat NB, Koutsky LA. Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis. 2008;198(7):971–8.CrossRefPubMedGoogle Scholar
  60. 60.
    Wallin KL, Wiklund F, Angstrom T, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med. 1999;341:1633–8.CrossRefPubMedGoogle Scholar
  61. 61.
    Frazer IH. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology. 2009;384:410–4.CrossRefPubMedGoogle Scholar
  62. 62.
    Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244–65.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Datta SD, Koutsky LA, Ratelle S, et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003–2005. Ann Intern Med. 2008;148:493–500.CrossRefPubMedGoogle Scholar
  64. 64.
    de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607–15.CrossRefPubMedGoogle Scholar
  65. 65.
    Dochez C, Bogers JJ, Verhelst R, Rees H. HPV vaccines to prevent cervical cancer and genital warts: an update. Vaccine. 2014;32:1595–601.CrossRefPubMedGoogle Scholar
  66. 66.
    Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364:401.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365:1576.CrossRefPubMedGoogle Scholar
  68. 68.
    FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915.CrossRefGoogle Scholar
  69. 69.
    Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928.CrossRefPubMedGoogle Scholar
  70. 70.
    Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301.CrossRefPubMedGoogle Scholar
  71. 71.
    Skinner SR, Szarewski A, Romanowski B, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet. 2014;384:2213.CrossRefPubMedGoogle Scholar
  72. 72.
    Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372:711.CrossRefGoogle Scholar
  73. 73.
    Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63:1.PubMedGoogle Scholar
  74. 74.
    Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis. 2010;202:1246.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Kojic EM, Kang M, Cespedes MS, et al. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis. 2014;59:127.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Hildesheim A, Wacholder S, Catteau G, Struyf F, Dubin G, Herrero R, CVT Group. Efficacy of the HPV-16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine. 2014;32(39):5087–97. doi: https://doi.org/10.1016/j.vaccine.2014.06.038.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Macartney KK, Chiu C, Georgousakis M, Brotherton JM. Safety of human papillomavirus vaccines: a review. Drug Saf. 2013;36(6):393–412.CrossRefPubMedGoogle Scholar
  78. 78.
    Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009;302:750.CrossRefPubMedGoogle Scholar
  79. 79.
    Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother. 2014;10:2147.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Ferris D, Samakoses R, Block SL, et al. Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics. 2014;134:e657.CrossRefPubMedGoogle Scholar
  81. 81.
    Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA. 1999;282:331.CrossRefPubMedGoogle Scholar
  82. 82.
    Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 2002;347:1652–61.CrossRefPubMedGoogle Scholar
  83. 83.
    Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med. 2012;366(1):34–43.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Springett VH, Sutherland I. A re-examination of the variations in efficacy of BCG vaccination against tuberculosis in clinical trials. Tuber Lung Dis. 1994;75:227–33.CrossRefPubMedGoogle Scholar
  85. 85.
    Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet. 2006;367:1173–80.CrossRefPubMedGoogle Scholar
  86. 86.
    Lalvani A, Millington KA. T cell-based diagnosis of childhood tuberculosis infection. Curr Opin Infect Dis. 2007;20:264–71.CrossRefPubMedGoogle Scholar
  87. 87.
    Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S, Snell L, Mangtani P, Adetifa I, Lalvani A, Abubakar I. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ. 2014;349:g4643.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Kumar B, Rai R, Kaur I, Sahoo B, Muralidhar S, Radotra BD. Childhood cutaneous tuberculosis: a study over 25 years from northern India. Int J Dermatol. 2001;40:26–32.CrossRefPubMedGoogle Scholar
  89. 89.
    Zodpey SP, Shrikhande SN, Maldhure BR, Kulkarni SW. Effectiveness of Bacillus Calmette Guerin (BCG) vaccination in the prevention of tuberculosis of skin: a case control study. Indian J Dermatol. 1998;43:4–6.Google Scholar
  90. 90.
    Singal A, Sonthalia S. Cutaneous tuberculosis in children: the Indian perspective. Indian J Dermatol Venereol Leprol. 2010;76(5):494–503.CrossRefPubMedGoogle Scholar
  91. 91.
    Ramesh V, Misra RS, Beena KR, Mukherjee A. A study of cutaneous tuberculosis in children. Pediatr Dermatol. 1999;16:264–9.CrossRefPubMedGoogle Scholar
  92. 92.
    Azulay RD. Antileprosy vaccinations. An Bras Dermatol. 2002;77(4):489–94.Google Scholar
  93. 93.
    Setia MS, Steinmaus C, Ho CS, Rutherford GW. The role of BCG in prevention of leprosy: a meta-analysis. Lancet Infect Dis. 2006;6:162–70.CrossRefPubMedGoogle Scholar
  94. 94.
    Merle CS, Cunha SS, Rodrigues LC. BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control. Expert Rev Vaccines. 2010;9:209–22.Google Scholar
  95. 95.
    Goulart IM, Bernardes Souza DO, Marques CR, Pimenta VL, Goncalves MA, Goulart LR. Risk and protective factors for leprosy development determined by epidemiological surveillance of household contacts. Clin Vaccine Immunol. 2008;15:101–5.CrossRefPubMedGoogle Scholar
  96. 96.
    Convit J, Sampson C, Zuniga M, Smith PG, Plata J, Silva J, et al. Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary results. Lancet. 1992;339:446–50.CrossRefPubMedGoogle Scholar
  97. 97.
    Karonga Prevention Trial Group. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet. 1996;348:17–24.CrossRefGoogle Scholar
  98. 98.
    Cunha SS, Alexander N, Barreto ML, Pereira ES, Dourado I, de Fatima Maroja M, et al. BCG revaccination does not protect against leprosy in the Brazilian Amazon: a cluster randomised trial. PLoS Negl Trop Dis. 2008;2:e167.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Handjani F, Delir S, Sodafi M, et al. Lupus vulgaris following bacille Calmette–Guérin vaccination. Br J Dermatol. 2001;144:444–5.CrossRefPubMedGoogle Scholar
  100. 100.
    Atasoy M, Aliagaoglu C, Erdem T, et al. Scrofuloderma following BCG vaccinatiosn. Pediatr Dermatol. 2005;22:179–80.CrossRefPubMedGoogle Scholar
  101. 101.
    Muto J, Kuroda K, Tajima S. Papular tuberculides post-BCG vaccination: case report and review of the literature in Japan. Clin Exp Dermatol. 2006;31:611–2.CrossRefPubMedGoogle Scholar
  102. 102.
    Inque T, Fukumoto T, Ansai S, et al. Erythema induratum of Bazin in an infant after bacille Calmette–Guerin vaccination. J Dermatol. 2006;33:268–72.CrossRefGoogle Scholar
  103. 103.
    Zodpey SP. Deciphering the story of Bacillus Calmette Guerin (BCG) vaccine in prevention of leprosy. Indian J Public Health. 2006;50(2):67–9.PubMedGoogle Scholar
  104. 104.
    Brazilian Ministry of Health. Guia para o Controle da hanseníase. Brasília; 2002.Google Scholar
  105. 105.
    Duppre NC, Camacho LA, da Cunha SS, Struchiner CJ, Sales AM, Nery JA, et al. Effectiveness of BCG vaccination among leprosy contacts: a cohort study. Trans R Soc Trop Med Hyg. 2008;102(7):631–8.CrossRefPubMedGoogle Scholar
  106. 106.
    Richardus RA, Butlin CR, Alam K, Kundu K, Geluk A, Richardus JH. Clinical manifestations of leprosy after BCG vaccination: an observational study in Bangladesh. Vaccine. 2015;33(13):1562–7.CrossRefPubMedGoogle Scholar
  107. 107.
    Status of vaccine research and development of vaccines for herpes simplex virus [internet]. Geneva: World Health Organization [cited 2016]. Available from: http://www.who.int/immunization/research/meetings_workshops/HSV_vaccineRD_Sept2014.pdf.
  108. 108.
    Silver B, Zhu H. Varicella zoster virus vaccines: potential complications and possible improvements. Virol Sin. 2014;29(5):265–73.CrossRefPubMedGoogle Scholar
  109. 109.
    Duthie MS, Gillis TP, Reed SG. Advances and hurdles on the way toward a leprosy vaccine. Hum Vaccin. 2011;7(11):1172–83.CrossRefPubMedPubMedCentralGoogle Scholar

Suggested Literature

  1. World Health Organization. Information about available and “in development” vaccines in world. Available at: http://www.who.int/immunization/diseases/en/.
  2. American Academy of Pediatrics. Red book: 2015. Report of the Committee on Infectious Diseases. In: Kimberlin DW, Brady MT, Jackson MA, Long SS (editors). 30th ed. Elk Grove Village; 2015. Available for subscribers at: http://redbook.solutions.aap.org/redbook.aspx.
  3. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practice (ACIP). General recommendations on use of vaccines in USA. Available at: http://www.cdc.gov/vaccines/acip/.

Copyright information

© Springer International Publishing Switzerland 2018

Authors and Affiliations

  1. 1.University Hospital, Luteran University of Brazil, ULBRACanoasBrazil

Personalised recommendations